Clinical trials: Dermatitis Atopic
Atopic Dermatitis, Eczema
HPA Axis Study in Japanese Adults
A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.
- Trial name
- NCT01407510
- Testing
- Mapracorat
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Atopic Dermatitis
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
- Trial name
- MARBLE-23 (NCT04717310)
- Testing
- SHR0302 Ointment, Vehicle
- Where
- 31 sites in China
- Volunteers
- 645 people
- Sponsor
- Reistone Biopharma Company Limited
Dermatitis, Atopic
A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects
To assess the pharmacokinetics of 3 doses and the food effect of a single high dose of BBI-5000 capsules in healthy adult subjects.
- Trial name
- NCT02590289
- Testing
- BBI-5000
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fresh Tracks Therapeutics, Inc.
Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as…
- Trial name
- ZENITH AD-2 (NCT07711418)
- Testing
- Rezpegaldesleukin
- Where
- 13 sites in United States
- Volunteers
- 510 people
- Sponsor
- Nektar Therapeutics
Atopic Dermatitis
A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis
- Trial name
- NCT04256174
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Akesobio Australia Pty Ltd
Pruritus, Atopic Dermatitis
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to…
- Trial name
- KARE (NCT04018027)
- Testing
- difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg
- Where
- 40 sites in United States, Canada
- Volunteers
- 401 people
- Sponsor
- Cara Therapeutics, Inc.
Atopic Dermatitis
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
- Trial name
- Adoring (NCT07265479)
- Testing
- Tapinarof cream, 1%, Vehicle Cream
- Where
- 46 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
- Trial name
- NCT04875169
- Testing
- Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Extension Treatment Active Experimental: SHR0302 Dose#1
- Where
- 52 sites in Canada, China
- Volunteers
- 336 people
- Sponsor
- Reistone Biopharma Company Limited
Dermatitis Atopic
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ESTUARY (NCT06407934)
- Testing
- Amlitelimab
- Where
- 324 sites in United States, Argentina and 25 more
- Volunteers
- 1,541 people
- Sponsor
- Sanofi
Atopic Dermatitis
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate Atopic Dermatitis.
- Trial name
- NCT03107611
- Testing
- Pimecrolimus Cream, 1%
- Where
- 27 sites in United States, Dominican Republic and 1 more
- Volunteers
- 654 people
- Sponsor
- Mylan Inc.
Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis
- Trial name
- NCT07598383
- Testing
- VC005 group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
Primary objective: To evaluate the efficacy of subcutaneous (SC) administration of tralokinumab compared with placebo in treating adolescent subjects (age 12 to <18 years) with moderate-to-severe AD.
- Trial name
- NCT03526861
- Testing
- Tralokinumab
- Where
- 87 sites in United States, Australia and 8 more
- Volunteers
- 301 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis
In this study, we will test the tolerance of a topical product and its efficacy in reducing the atopy crisis duration and severity.
- Trial name
- NCT05531188
- Where
- Mauritius
- Volunteers
- 68 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03912259
- Testing
- Dupilumab, Emollient (moisturizer)
- Where
- 27 sites in China
- Volunteers
- 165 people
- Sponsor
- Sanofi
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
A Study of MG-K10 in Subjects With Atopic Dermatitis
This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.
- Trial name
- NCT05466877
- Testing
- MG-K10
- Where
- 2 sites in China
- Volunteers
- 163 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis, Sleep Disturbance
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
Many people with atopic dermatitis (AD) experience sleep disturbances. Greater sleep disturbances are associated with greater burden including increased sick days and impaired cognition.
- Trial name
- Sleep Up (NCT06390722)
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Dermatitis, Atopic
A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-39758979 in adult Japanese patients with moderate, active atopic dermatitis.
- Trial name
- NCT01497119
- Testing
- JNJ-39758979, 300 mg, JNJ-39758979, 100 mg
- Where
- 13 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Janssen Pharmaceutical K.K.
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.